Overview

A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension

Status:
Completed

Trial end date:
2004-07-01

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Alcon Research

Treatments:

Brimonidine Tartrate
Ophthalmic Solutions
Pharmaceutical Solutions